Back to News & Events

Funding Opportunity for SBU Researchers: Development and Commercialization of Bio-Based Technologies for Human Health 

The Center for Biotechnology on behalf of the Long Island Bioscience Hub is pleased to announce a request for proposals for our two-tiered technology development & commercialization program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo).  More information can be found thru this link (or view on CfB web-page)… 

Review the full funding program overview and proposal guidelines

Stony Brook University faculty and postdoctoral associates, alone or in partnership with companies or CFB-appointed BioEntrepreneurs-in-Residence (BEIRs), are eligible to apply. In all instances, the faculty member or post-doctoral associate must serve as the principal investigator, and the project must be executed on the academic campus at Stony Brook University.

Application Deadline: March 7, 2024 no later than 5pm.

Interested applicants are strongly recommended to connect with the Center for Biotechnology team before writing a full proposal and submission.  
Please contact Phuong Nguyen, PhD, at the Center for Biotechnology: phuong.t.nguyen@stonybrook.edu.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2062 [post_author] => 3 [post_date] => 2015-11-23 20:09:45 [post_date_gmt] => 2015-11-23 20:09:45 [post_content] => Biotechnology Strategist Brian McCarthy and Pharma Executive Gian Luca Araldi selected to launch new bioscience companies STONY BROOK, N.Y. – November 23, 2015 – The Center for Biotechnology at Stony Brook University announced today the appointment of Brian McCarthy, PhD and Gian Luca Araldi, PhD, as BioEntrepreneurs-In-Residence (B-EIR) for the Long Island Bioscience Hub.  The Long Island Bioscience Hub is a National Institutes of Health-designated Research Evaluation and Commercialization Hub, and represents a partnership between Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, to commercialize technology emerging from their institutions. Drs. McCarthy and Araldi have broad bioscience industry experience and comprehensive knowledge of commercializing academic technologies. In their roles as BEIR they will identify technologies that have the potential to support company formation in the region.  Each brings unique skills and perspectives to technology assessment and bioscience-startups. Dr. McCarthy is a senior biotechnology strategist with operational, start-up, development, and financial expertise. He currently serves as a business advisor to Gismo Therapeutics Inc. and VP of Business and Clinical Development at Viatar CTC Solutions Inc. Prior to his Wall Street and entrepreneurial career, Dr. McCarthy was a faculty member at Cornell University Medical College and the National Naval Medical Center. Dr. McCarthy received his PhD in Neurobiology from Stony Brook University. Dr. Araldi is a pharmaceutical and biotechnology executive with more than 25 years of experience ranging from basic research through clinical development at major pharmaceutical companies including Glaxo, Forest Laboratories and Merck-Serono.  Dr. Araldi has been involved in the development of key medicines such as Teflaro®, Dutogliptin®, Gavestinel®, Sanfetrinem® and Sanfetrinem® Cilexetil and is the inventor of 113 granted patents. Dr. Araldi received doctorate degrees in Organic Chemistry and Pharmacy from the University of Parma (Italy) and recently received his M.B.A. in Finance from Long Island University Post. “The Long Island Bioscience Hub is excited to announce the appointments of Drs. McCarthy and Araldi as BioEntrepreneurs-in-Residence” Diane Fabel, Director of Operations for the Center for Biotechnology stated. “They join a talented roster of five existing BioEntrepreneurs in Residence at the Center for Biotechnology who are well on their way to commercializing technologies and building their companies.” As B-EIRs Drs. McCarthy and Araldi are tasked with identifying technology or technologies from within the partner institutions that will create the foundation for licensing and company formation.  They will have the support of the LIBH business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. The LIBH can also provide access to a competitive pool of technology development funding to help move their technologies down a commercial pathway.  Ultimately, the goal is to help the company position itself prepare for SBIR/STTR grant opportunities, and Angel and VC investment. [post_title] => Long Island Bioscience Hub Selects Bioentrepreneurs-In-Residence [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-bioscience-hub-selects-bioentrepreneurs-in-residence [to_ping] => [pinged] => [post_modified] => 2016-03-29 20:13:28 [post_modified_gmt] => 2016-03-29 20:13:28 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2062 [menu_order] => 197 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3583 [post_author] => 3 [post_date] => 2020-07-16 10:33:42 [post_date_gmt] => 2020-07-16 10:33:42 [post_content] => Long Island Headquartered Enzo Biochem, Inc. and Farmingdale State College have announced they are partnering to provide molecular and antibody testing for COVID-19 to the campus community as the college reopens this summer and begins classes in the fall. LIBMI Mentor & CFB Advisor, Kara Cannon, Enzo’s Chief Commercial Officer commented, “Enzo is launching its School and Institution Testing (“SIT”) Program to ensure well-being, security, and compliance at educational and religious institutions. Farmingdale State College is the first to leverage Enzo’s expertise and enable this academic institution to safely forge a course forward this summer into the fall.” Read the full press release on the partnership here. [post_title] => Enzo & Farmingdale State College Partner on Campus COVID Testing [post_excerpt] => Enzo Biochem, Inc. and Farmingdale State College are partnering to provide testing for COVID-19 to the campus community this fall. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => enzo-farmingdale-state-college-partner-on-campus-covid-testing [to_ping] => [pinged] => [post_modified] => 2020-09-14 14:22:27 [post_modified_gmt] => 2020-09-14 14:22:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3583 [menu_order] => 60 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3418 [post_author] => 3 [post_date] => 2020-01-14 15:43:38 [post_date_gmt] => 2020-01-14 15:43:38 [post_content] => Farmingdale, New York based Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, has announced the closing of a $20 million Series B investment round. The new investment was led by Adjuvant Capital, with participation by Euclidean Capital and Topspin Partners. The funds will be used to support the further clinical development of Codagenix's live attenuated RSV vaccine for the elderly, a broadly-protective influenza vaccine and an oncolytic virus therapy for triple negative breast cancer (TNBC). This funding round, combined with Series A investments, brings Codagenix's total funding to $38 million. Previous funders include Topspin Partners, the Center for Biotechnology and various U.S. government agencies. More. [post_title] => Codagenix Announces $20M Series B [post_excerpt] => CFB Client, Codagenix, has announced the closing of a $20 million Series B investment round. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => codagenix-announces-20m-series-b [to_ping] => [pinged] => [post_modified] => 2020-01-14 15:43:38 [post_modified_gmt] => 2020-01-14 15:43:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3418 [menu_order] => 79 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Long Island Bioscience Hub Selects Bioentrepreneurs-In-Residence

More Information

Enzo & Farmingdale State College Partner on Campus COVID Testing

More Information

Codagenix Announces $20M Series B

More Information